• Nuclear Medicine and Molecular Imaging
• /
• v.41 no.1
• /
• pp.68-69
• /
• 2007

A 44-year-old female underwent three-phase bone scintigraphy for an evaluation of right hip joint pain. The blood-flow and blood-pool images show a pelvic blush with a photopenic center (doughnut) prior to bladder filling. On the three hour delayed image, the pelvic uptake disappeared. The scintigraphic findings indicated the possibility of an early pregnancy. However, plain radiography demonstrated an intrauterine device. A uterine doughnut developed as a result of photon attenuation of intrauterine device.

• Asian-Australasian Journal of Animal Sciences
• /
• v.16 no.2
• /
• pp.180-184
• /
• 2003

The intrauterine inseminator (IUI) was developed to provide the method of depositing dog semen into the uterine body instead of the vagina. The IUI consists of a vaginal endoscope, a balloon sheath, and injection catheter. When the endoscope is inserted into the vagina and the balloon expanded with air, the cervical os becomes visible so a injection catheter can be inserted through the cervix for deposition of the frozen-thawed semen. The efficacy of the IUI device was compared to intra-vaginal artificial insemination using semen that had been collected and frozen from pooled sperm-rich fraction of ejaculates collected from two Jindo dog donors. Aliquots of semen were extended with a Tris-egg yolk diluent, centrifuged, the seminal plasma removed, the pellet resuspended with the same diluent, and cooled to $5^{\circ}C$ over a 2 h period. A Tris-egg yolk-glycerol extender was added at $5^{\circ}C$; after 1 h, semen was loaded into 0.5 ml straws, and straws were frozen in LN vapor for 5 min, and immersed in LN for storage. The final sperm concentration for freezing was approximately $100{\times}10^{6}cells/ml$. The straws were thawed at $70^{\circ}C$ for precisely 6 sec, 1.5 ml Tris-egg yolk buffer at $38^{\circ}C$ added, and the 2 ml of thawed semen was used for a single insemination using the IUI device. Each bitch was inseminated at optimal insemination point, which was estimated by vaginal epithelial cells staining and progesterone concentration analysis. Use of the IUI device resulted in 21 of 26 females giving birth to 89 pups ($4.2{\pm}1.6$ pups per litter), while intra-vaginal AI resulted in 6 of 15 females whelping a total of 17 pups ($2.8{\pm}1.2$ pups per litter). We believe the IUI device is easier to use than previously described devices used for intrauterine insemination. In our experience the expansion of the balloon has a calming effect on the bitch that aids the inseminator. These results indicate that the IUI device was able to provide high fertility with 50 million frozen sperm per insemination and two inseminations.

• Women's Health Nursing
• /
• v.26 no.4
• /
• pp.300-317
• /
• 2020

Purpose: Hysteroscopy can be used both to diagnose and to treat intrauterine pathologies. It is well known that hysteroscopy helps to improve reproductive outcomes by treating intrauterine pathologies. However, it is uncertain whether hysteroscopy is helpful in the absence of intrauterine pathologies. This study aimed to confirm whether hysteroscopy improves the reproductive outcomes of infertile women without intrauterine pathologies. Methods: We conducted a systematic review of 11 studies retrieved from Ovid-MEDLINE, Ovid-Embase, and the Cochrane Library. Two independent investigators extracted the data and used risk-of-bias tools (RoB 2.0 and ROBINS-I) to assess their quality. Results: Diagnostic hysteroscopy prior to in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) was associated with a higher clinical pregnancy rate (CPR) and live birth rate (LBR) than non-hysteroscopy in patients with recurrent implantation failure (RIF) (odds ratio, 1.79 and 1.46; 95% confidence interval, 1.40-2.30 and 1.08-1.97 for CPR and LBR, respectively) while hysteroscopy prior to first IVF was ineffective. The overall meta-analysis of LBR showed statistically significant findings for RIF, but a subgroup analysis showed effects only in prospective cohorts (odds ratio, 1.40 and 1.47; 95% confidence interval, 0.62-3.16 and 1.04-2.07 for randomized controlled trials and prospective cohorts, respectively). Therefore, the LBR should be interpreted carefully and further research is needed. Conclusion: Although further research is warranted, hysteroscopy may be considered as a diagnostic and treatment option for infertile women who have experienced RIF regardless of intrauterine pathologies. This finding enables nurses to educate and support infertile women with RIF prior to IVF/ICSI.

• Clinical and Experimental Reproductive Medicine
• /
• v.20 no.2
• /
• pp.183-186
• /
• 1993

Pelvic actinomyces, usually a complication of an intrauterine device, is uncommon and may present a diagnostic dilemma because of an atypical clinical presentation. This organism is very difficult to culture, and most actinomyces is actually identified by histologic feature in pathologic specimens. Authors have experienced a case of pelvic actinomycosis associated with an intrauterine device and reported with a review of literatures.

• Investigative Magnetic Resonance Imaging
• /
• v.23 no.2
• /
• pp.136-141
• /
• 2019

Pelvic actinomycosis is an uncommon infectious disease. It induces a chronic, suppurative illness characterized by an infiltrative and granulomatous response and, thus, the clinical and radiologic findings may mimic other inflammatory and neoplastic conditions. A 56-year-old female with a long-standing intrauterine device was diagnosed with pelvic actinomycosis manifesting as a large uterine mass with locally infiltrative spread into surrounding tissue that mimicked uterine malignancy. Actinomyces israelii infection was confirmed with a surgical specimen, and the patient was treated with antibiotic medication. Pelvic actinomycosis must be included in the differential diagnoses of patients with an infiltrative pelvic mass extending across tissue planes or in patients with findings of multiple microabscesses, particularly in a patient with an intrauterine device, even the lesion primarily involves the uterus.

• Clinical and Experimental Reproductive Medicine
• /
• v.32 no.4
• /
• pp.353-359
• /
• 2005

Heterotopic pregnancy is named when an extrauterine (ectopic) pregnancy coexists with an intrauterine pregnancy simultaneously by many causes such as PID (pelvic inflammatory disease), endometriosis, IUD (intrauterine device), previous pelvic surgery and others. This is very rare in general population, with a range of occurrence estimated between 1:7963 and 1:30000. But recently the incidence has increased as the uses of ARTs (assisted reproductive technologies) including ovulation induction, IVF-ET (in-vitro fertilization and embryo transfer) and GIFT (gamete intrafallopian transfer) increase. Because this has high maternal morbidity, mortality and fetal loss, early diagnosis and proper management is very important. We report a case of heterotopic pregnancy following IVF-ET with a brief review.

• Journal of Pharmaceutical Investigation
• /
• v.11 no.3
• /
• pp.14-20
• /
• 1981

One of the major objectives in the developments of a progesterone I.U.D. is to prepare devices which release drug at a constant rate for extended periods. A constant release rate is achived by maintaining drug concentration at a constant valve via the introduction of rate limiting membrane to solute diffusion at the surface of the devices. In this study, progesterone dispersed at monolithic device were prepared from polyhydroxy ethyl methacrylate. Constant release rate were obtained with device which were soaked in on ethanol-hexan solution. The release rate was dependant upon the concentration of the ethanolic solution in the soaking solution. This devices offer significant potential for futher development of hydrogel in the intrauterine contraception device for controlled release of progesterone.

• Clinical and Experimental Reproductive Medicine
• /
• v.11 no.1
• /
• pp.33-37
• /
• 1984

A nornal pregnancy with IUD in situ, which is extremely rare case, is reported with the brief reviews of literatures. And assoc i at i on between intrauterine device and pelvic inflammatory disease is also rported.

• Journal of Veterinary Clinics
• /
• v.38 no.4
• /
• pp.199-203
• /
• 2021

A 4-year-old Thoroughbred mare was brought to the Korea Racing Authority Equine Hospital with heightened sensitivity to touch of the hindquarter, reluctance to step forward, frequent urination even during training, clitoral winking, tail swinging, tail lifting, and training difficulties due to being in constant heat. The trainer claimed that she was in heat and exhibited reduced performance. Physical and lameness examinations revealed no abnormality. Rectal palpation and transrectal ultrasonography revealed normal reproductive organs and estrus. As she exhibited typical estrous behavior without any other physical conditions, the mare was considered to express undesirable estrous behavior. An intrauterine glass ball was inserted into the mare on ovulation day. However, the estrous behaviors were reduced unsatisfactorily. Additionally, 1 mL of peanut oil was administered on the 10th day after the intrauterine device insertion. The mare returned to training and expressed no undesirable estrous behavior over 30 days after the peanut oil treatment. However, further follow-ups were not conduct as the mare was retired to a farm after a limb injury occurred during training. This is the first report of undesirable estrous behavior in a Thoroughbred mare under the rules of racing in Korea. It is recommended that equine clinicians in Korea consider peanut oil as a therapeutic agent to control mares' estrous behavior-related problems.

• The Korean Society of Law and Medicine
• /
• v.15 no.2
• /
• pp.63-89
• /
• 2014

In 1976, the Dalkon Shield-intrauterine device injured several thousand women in U.S.A. which caused the changes of medical deivce regulation. The Medical Device Regulation Act or Medical Device Amendments of 1976 (MDA) was introduce. As part of the process of regulating medical devices, the MDA divides medical devices into three categories. The class II, and III devices which have moderate harm or more can use the section 510 (k), premarket notification process if the manufacturer can establish that its device is "substantially equivalent" to a device that was marketed before 1976. In 21 U.S.C. ${\S}$ 360k(a), MDA introduced a provision which expressly preempts competing state laws or regulations. After that, the judicial debates had began over the proper interpretation and application of Section 360(k) In February 2008, the U.S. Supreme Court ruled in Riegel v. Medtronic that manufacturer approved by the Food and Drug Administration (FDA)'s pre-market approval process are preempted from liability, even when the devices have defective design or lack of labeling. But the Supreme Court ruled in Medtronic Inc. v. Lora Lohr that the manufactures which use the section 510 (k) process cannot be preempted and in Bausch v. Stryker Corp. that manufactures which violated the CGMP standard are also liable to the damage of patient at the state courts. In 2009, the Supreme Court ruled in Wyeth v. Levine that patients harmed by prescription drugs can claim damages in state courts. This may cause a double standard between prescription drugs and medical devices. FDA Preemption is the legal theory in the United States that exempts product manufacturers from tort claims regarding Food and Drug Administration approved products. FDA Preemption has been a highly contentious issue. In general, consumer groups are against it while the FDA and pharmaceutical manufacturers are in favor of it. This issues also influences the theory of product liability of U.S.A. Complete immunity preemption is an issue need to be more declared.